dan 2163 has been researched along with pergolide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrieux, M; Besançon, R; Giros, B; Martres, MP; Pilon, C; Schwartz, JC; Sokoloff, P | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Burlon, M; Göhring, K; Gruschka, P; Kaiser, S; Pfüller, U; Roesch-Ely, D; Weisbrod, M | 1 |
3 other study(ies) available for dan 2163 and pergolide
| Article | Year |
|---|---|
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Topics: Animals; Chlorides; CHO Cells; Cricetinae; Dopamine; Dopamine Agents; Dopamine Antagonists; Guanylyl Imidodiphosphate; Humans; Lithium; Lithium Chloride; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3; Sodium Chloride; Sulpiride; Transfection | 1992 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Comorbidity; Depressive Disorder; Dopamine Agonists; Drug Therapy, Combination; Frontal Lobe; Hallucinations; Humans; Male; Neural Pathways; Pergolide; Psychiatric Status Rating Scales; Receptors, Dopamine D1; Receptors, Dopamine D2; Schizophrenia, Paranoid; Sulpiride; Treatment Outcome | 2006 |